Product Details
Alternative Name: | Apo-2L, TNFSF 10, CD253 |
|
Applications: | FUNC
|
|
Application Notes: | Induces apoptosis in a concentration range of 1-100ng/ml if applied with the cross-linking enhancer. |
|
Species reactivity: | Human, Mouse
|
|
Specificity: | TRAIL binds to human and mouse TRAIL receptors and human osteoprotegerin (OPG). |
|
Specific Activity: | ED50: 10ng/ml (Jurkat cells) |
|
Purity: | ≥95% (SDS-PAGE) |
|
Contents: | 10µg of TRAIL, Soluble (human) (recombinant) (Prod. No. ALX-522-003) and 2x50µg of Enhancer for Ligands (Prod. No. ALX-804-034). |
|
Formulation: | Lyophilized. Contains PBS. |
|
Reconstitution: | Reconstitute TRAIL with 100µl and each vial of enhancer with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum. |
|
Concentration: | TRAIL: 0.1mg/ml after reconstitution
Enhancer: 1mg/ml after reconstitution |
|
Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
|
Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
|
Shipping: | Blue Ice |
|
Long Term Storage: | -20°C |
|
Source: | Produced in E. coli. The extracellular domain of human TRAIL (Apo-2L) (aa 95-281) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag. |
|
Technical Info/Product Notes: | FLAG is a registered trademark of Sigma-Aldrich Co. |
|
UniProt ID: | P50591 |
|
Regulatory Status: | RUO - Research Use Only |
|
Product Literature References
Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization: M. Li, et al.; Biochem. Biophys. Res. Commun.
495, 1376 (2018),
Abstract;
Human mast cells undergo TRAIL-induced apoptosis: B. Berent-Maoz, et al.; J. Immunol.
176, 2272 (2006),
Abstract;
Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells: S. Lacour, et al.; Oncogene
22, 1807 (2003),
Abstract;
Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells: J.D. Lunemann, et al.; J. Immunol.
168, 4881 (2002),
Abstract;
Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils: I. Daigle, et al.; Nat. Med.
8, 61 (2002),
Abstract;
Induction of TRAIL-mediated glioma cell death by human T cells: J. Dörr, et al.; J. Neuroimmunol.
122, 117 (2002),
Abstract;
Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling in Activated T Cells Abrogates TRAIL-Induced Apoptosis Upstream of the Mitochondrial Amplification Loop and Caspase-8: T.S. Soderstrom, et al.; J. Immunol.
169, 2851 (2002),
Abstract;
Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L): R. Ravi & A. Bedi; Cancer Res.
62, 1583 (2002),
Abstract;
TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections: J. Strater, et al.; Gastroenterology
122, 659 (2002),
Abstract;
TRAIL/Apo-2 ligand induces primary plasma cell apoptosis: J. Ursini-Siegel, et al.; J. Immunol.
169, 5505 (2002),
Abstract;
Full Text
Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells: C. Xiao, et al.; J. Biol. Chem.
277, 25020 (2002),
Abstract;
Full Text
A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells: V. Screpanti, et al.; J. Immunol.
167, 2068 (2001),
Abstract;
Full Text
Caspase-10 is an initiator caspase in death receptor signaling: J. Wang, et al.; PNAS
98, 13884 (2001),
Abstract;
Full Text
NF-κB signals induce the expression of c-FLIP: O. Micheau, et al.; Mol. Cell. Biol.
21, 5299 (2001),
Abstract;
Full Text
The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines: Q. Liao, et al.; FEBS Lett.
503, 151 (2001),
Abstract;
Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2: C.A. Benedict et al.; J. Biol. Chem.
276, 3270 (2001),
Abstract;
Full Text
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan: M. Dejosez, et al.; Cell Death Differ.
7, 1127 (2000),
Abstract;
Full Text
General Literature References
Cell death: TRAIL and its receptors: P. Golstein; Curr. Biol.
7, R750 (1997),
Abstract;
How TRAIL kills cancer cells, but not normal cells: T. Gura; Science
277, 768 (1997),
Abstract;
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family: R.M. Pitti, et al.; J. Biol. Chem.
271, 12687 (1996),
Abstract;
Identification and characterization of a new member of the TNF family that induces apoptosis: S.R. Wiley, et al.; Immunity
3, 673 (1995),
Abstract;
Related Products